These data, along with TCGA analyses demonstrating co-occurrence of an MDSC-rich gene expression profile and a T-cell inflamed tumor phenotype, strongly support combining MDSC-targeting therapeutic strategies with CTLA-4-based checkpoint inhibition in the clinical setting. This evidence concerns the gene CTLA4 and neoplasm.